Grail shares surge ahead of FDA advisory meeting on documents
Shares of Grail surged 34% after the FDA released documents ahead of a Wednesday advisory committee meeting on whether the company’s multi-cancer blood test will be approved.
Shares of Grail rose 34% on Monday after the Food and Drug Administration released documents ahead of a Wednesday advisory committee meeting that will help determine whether the FDA approves the company’s multi-cancer blood test. Galleri looks for chemical tags on DNA that tumors s…